Enhancer of zeste homolog 2 inhibitor, EPZ-6438, restored the susceptibility to sorafenib in resistant thyroid carcinoma cells in vitro and in vivo through decreasing the trimethylation of histone H3 at lysine 27 (H3K27me3) and increasing the acetylated lysine 27 of histone H3 (H3K27ac) levels [43]. The gene discussed is EZH2; the disease is thyroid gland carcinoma.